Article Text

Download PDFPDF
Original research
Maternal cardiovascular risk after hypertensive disorder of pregnancy
  1. Clare Arnott1,2,3,4,
  2. Michael Nelson5,
  3. Maria Alfaro Ramirez5,
  4. Jon Hyett3,6,
  5. Marianne Gale7,
  6. Amanda Henry8,9,
  7. David S Celermajer1,3,
  8. Lee Taylor5,
  9. Mark Woodward10,11,12
  1. 1Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
  2. 2Cardiometabolic, George Institute for Global Health, Sydney, New South Wales, Australia
  3. 3Sydney Medical School, University of Sydney, Sydney, NSW, Australia
  4. 4Medicine, University of New South Wales, Sydney, NSW, Australia
  5. 5Centre for Epidemiology and Evidence, New South Wales Ministry of Health, Sydney, New South Wales, Australia
  6. 6Sydney Institute for Women, Children and their Families, Royal Prince Albert Hospital, Camperdown, New South Wales, Australia
  7. 7Office of the Chief Health Officer, New South Wales Ministry of Health, Sydney, New South Wales, Australia
  8. 8Maternal Health, George Institute for Global Health, Sydney, New South Wales, Australia
  9. 9School of Women’s and Children’s Health, University of New South Wales Faculty of Medicine, Sydney, New South Wales, Australia
  10. 10Epidemiology, Johns Hopkins University, Baltimore, MD, United States
  11. 11The George Institute for Global Health, University of Oxford, Oxford, Oxfordshire, UK
  12. 12The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
  1. Correspondence to Professor Mark Woodward, The George Instute for Global Health, Camperdown, NSW 2050, Australia; markw{at}georgeinstitute.org.au

Abstract

Background and objective Hypertensive disorders of pregnancy (HDPs) affect 5%–10% of pregnancies and have been associated with excess maternal cardiovascular disease (CVD) risk. The primary aim of this study was to reliably estimate absolute and relative risks of CVD after HDP.

Methods A retrospective cohort of women who had singleton pregnancies in New South Wales, Australia, between 2002 and 2016 and identified using linked population health administrative databases. The primary exposure was new-onset HDP (pre-eclampsia/eclampsia and gestational hypertension), and the endpoint was hospitalisation or death due to ischaemic or hypertensive heart disease, or stroke. Kaplan-Meier analysis estimated risks among mothers following their first birth, and multivariable time-dependent Cox regression estimated the association between HDP and CVD.

Results Among 528 106 women, 10.3% experienced HDP in their first pregnancy. The 10-year estimated risk of CVD was 2.1 per 1000 if no HDP and 5.5 per 1000 following HDP. Adjusting for demographics, gestational diabetes, small for gestational age and preterm birth, we found that there was an interaction between smoking and HDP, and a larger effect of early-onset (<34 weeks) HDP, compared with late-onset HDP. The HR for women with early-onset HDP who did not smoke was 4.90 (95% CI 3.00 to 7.80) and the HR for those who did smoke was 23.5 (95% CI 13.5 to 40.5), each compared with women without HDP who did not smoke.

Conclusion In this nationally representative Australian cohort, HDP, especially early onset, conferred a clear increase in the risk of CVD, with amplification by smoking. Targeted preventive health, during and after pregnancy, could prevent a substantial burden of CVD among childbearing women.

  • pregnancy
  • hypertension
  • smoking cessation
  • diabetes
View Full Text

Statistics from Altmetric.com

Footnotes

  • CA and MN are joint first authors.

  • Contributors All authors were involved in the design of the study. MN carried out the statistical analyses. CA and MW wrote the first complete draft of the paper. All other authors contributed to further drafts and approved the final manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

  • Funding MW is supported by the National Health and Medical Research Council of Australia (grant numbers 1080206 and 1149987). AH is supported by a National Health and Medical Research Council (Australia) Early Career Fellowship (1141570).

  • Competing interests MW has received consulting fees from Amgen, Inc, and Kyowa Kirin Co, Ltd.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Ethics approval Ethics approval was obtained from the NSW Population and Health Services Research Ethics Committee (reference number: 2018HRE0902). The study was conducted in accordance with the principles of the Declaration of Helsinki.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. No additional data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.